Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - codeine phosphate hemihydrate, quantity: 15 mg; paracetamol, quantity: 500 mg - tablet, uncoated - excipient ingredients: colloidal anhydrous silica; povidone; lactose monohydrate; docusate sodium; potato starch; magnesium stearate; ethanol; purified water - for the temporary relief of acute moderate pain in patients over the age of 12 years (see also contraindications and paediatric use)

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - codeine phosphate hemihydrate,doxylamine succinate,paracetamol -

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - codeine phosphate hemihydrate,paracetamol -

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

medreich australia pty ltd - codeine phosphate hemihydrate, quantity: 9.6 mg; paracetamol, quantity: 499.9995 mg - tablet, uncoated - excipient ingredients: microcrystalline cellulose; magnesium stearate; quinoline yellow aluminium lake; povidone; croscarmellose sodium; pregelatinised maize starch; maize starch; stearic acid; crospovidone - for the temporary relief of acute moderate pain in patients over the age of 12 years.

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - codeine phosphate hemihydrate,ibuprofen -

Ιρλανδία - Αγγλικά - HPRA (Health Products Regulatory Authority)

chefaro ireland dac - paracetamol; codeine phosphate hemihydrate; caffeine - capsule, hard - 500 mg/8 mg/30 milligram(s) - opioids in combination with non-opioid analgesics; codeine and paracetamol

Ιρλανδία - Αγγλικά - HPRA (Health Products Regulatory Authority)

chefaro ireland dac - paracetamol; codeine phosphate hemihydrate; caffeine - tablet - 500 mg/8 mg/30 milligram(s) - opioids in combination with non-opioid analgesics; codeine and paracetamol

Ιρλανδία - Αγγλικά - HPRA (Health Products Regulatory Authority)

bristol laboratories limited - codeine phosphate hemihydrate; paracetamol - effervescent tablet - 500/30 milligram(s) - opioids in combination with non-opioid analgesics; codeine and paracetamol

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

apotheca inc - codeine phosphate (unii: gsl05y1mn6) (codeine anhydrous - unii:ux6owy2v7j), promethazine hydrochloride (unii: r61zeh7i1i) (promethazine - unii:ff28ejq494) - codeine phosphate 10 mg in 5 ml - promethazine hydrochloride and codeine phosphate syrup is indicated for the temporary relief of coughs and upper respiratory symptoms associated with allergy or the common cold. the combination of promethazine hydrochloride and codeine phosphate is contraindicated in pediatric patients less than 6 years of age, because the combination may cause fatal respiratory depression in this age population. codeine sulfate is contraindicated for postoperative pain management in children who have undergone tonsillectomy and/or adenoidectomy. codeine is contraindicated in patients with a known hypersensitivity to the drug. promethazine is contraindicated in comatose states, and in individuals known to be hypersensitive or to have had an idiosyncratic reaction to promethazine or to other phenothiazines. antihistamines and codeine are both contraindicated for use in the treatment of lower respiratory tract symptoms, including asthma. promethazine hydrochloride and codeine phosphate syrup is a schedule v controlled substance

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

nexgen pharma, inc. - codeine phosphate (unii: gsl05y1mn6) (codeine anhydrous - unii:ux6owy2v7j), chlorpheniramine maleate (unii: v1q0o9oj9z) (chlorpheniramine - unii:3u6io1965u) - codeine phosphate 54.3 mg - codeine phosphate and chlorpheniramine maleate is indicated for the relief of cough and symptoms associated with upper respiratory allergies or a common cold in adults 18 years of age and older. important limitations of use not indicated for pediatric patients under 18 years of age [see use in special population (8.4)] patients with known hypersensitivity to codeine, chlorpheniramine or any of the inactive ingredients of codeine phosphate and chlorpheniramine maleate. persons known to be hypersensitive to certain other opioids may exhibit cross-sensitivity to codeine. teratogenic effects pregnancy category c there are no adequate and well-controlled studies of codeine phosphate and chlorpheniramine maleate in pregnant women. reproductive toxicity studies have not been conducted with codeine phosphate and chlorpheniramine maleate; however, studies are available with individual active ingredients or related active ingredients. because animal reproduction studies are not always predictive of human response, co